NCI Trial CDR0000562261
 

Does anyone know anything about NCI trial CDR0000562261? Has anyone participated? The objective of this trial is:

To determine if the GP2 peptide/GM-CSF vaccine reduces the recurrence rate in HLA-A2-positive, HER2/neu-positive, node-positive, or high-risk node-negative breast cancer patients randomized to receive the vaccine versus the immunoadjuvant, sargramostim (GM-CSF), alone.
To determine if the AE37 peptide/GM-CSF vaccine reduces the recurrence rate in HLA-A2-negative, HER2/neu-positive, node-positive or high-risk node-negative breast cancer patients randomized to receive the vaccine versus the immunoadjuvant, GM-CSF, alone.

I am trying to be proactive. I finished 28 rads almost a week ago (ouch) and will finish Herceptin on 12/28/12.


I am attaching the link:

http://www.cancer.gov/clinicaltrials...thprofessional

Re: NCI Trial CDR0000562261
 

I just finished my last booster shot in this clinical trial in June. SandraGA and ElizabethTX are also currently participating.